MindWalk Holdings (HYFT) Research & Development (2020 - 2026)
MindWalk Holdings (HYFT) posted quarterly Research & Development of $1146.1 for Q2 2026, up 29.43% year-over-year from $885.44 in Q2 2025, and down 99.87% quarter-over-quarter from $874771.6 in Q1 2026.
MindWalk Holdings (HYFT) Research & Development (2020 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has reported Research & Development for 7 consecutive years, with $1146.1 the latest figure, recorded in Q2 2026.
- In Q2 2026, Research & Development rose 29.43% year-over-year to $1146.1; the TTM figure through Apr 2026 stood at $877884.4 (down 99.92% YoY), while the FY2026 annual figure was $3.6 million, up 19.07% from the prior year.
- Research & Development declined to $1146.1 in Q2 2026 per HYFT's latest filing, from $874771.6 in the prior quarter.
- Across five years, Research & Development topped out at $1.1 billion in Q3 2024 and bottomed at $883.08 in Q4 2025.
- Historically, Research & Development has averaged $134.9 million across 5 years, with a median of $720875.9 in 2024.
- Annual changes were most pronounced in 2023 — Research & Development jumped 15792617.46% — and 2025, when it tumbled 100.0%.
- MindWalk Holdings' Research & Development stood at $3.8 million in 2022, then jumped by 16251.84% to $615.8 million in 2023, then plunged by 99.88% to $736682.4 in 2024, then slumped by 99.88% to $883.08 in 2025, then climbed by 29.78% to $1146.1 in 2026.
- Business Quant data shows HYFT's Research & Development at $1146.1 in Q2 2026, $874771.6 in Q1 2026, and $883.08 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 202.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 1,146.05 |
| Jan 31, 2026 | 874,771.62 |
| Oct 31, 2025 | 883.08 |
| Jul 31, 2025 | 1,083.67 |
| Apr 30, 2025 | 885.44 |
| Jan 31, 2025 | 643,846.14 |
| Oct 31, 2024 | 736,682.43 |
| Jul 31, 2024 | 1.09 Bn |
| Apr 30, 2024 | 705,069.39 |
| Jan 31, 2024 | 740,461.20 |
| Oct 31, 2023 | 615.81 Mn |
| Jul 31, 2023 | 709.50 Mn |
| Apr 30, 2023 | 674,012.85 |
| Jan 31, 2023 | 1.16 Mn |
| Oct 31, 2022 | 3.77 Mn |
| Jul 31, 2022 | 4,492.55 |
| Apr 30, 2022 | 6.05 Mn |
| Jan 31, 2022 | 1,437.95 |
| Oct 31, 2021 | 2,265.41 |
| Jul 31, 2021 | 910,847.02 |